Participants Needed for PTSD Clinical Trial At Stanford University / VA Medical Facility In Palo Alto, California

08/28/2013

ClinicalTrials.gov

A service of the U.S. National Institutes of Health
Trial record 1 of 2 for:    TMS AND PTSD AND CALIFORNIA
Previous Study         | Return to List |          Next Study

Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD)

      This study is currently recruiting participants.
Verified January 2012 by Stanford University
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Stanford University
ClinicalTrials.gov Identifier:
NCT01507948
First received: December 14, 2011
Last updated:  January 13, 2012
Last verified:  January 2012

  Purpose

The investigators are seeking people who have been exposed to a traumatic event in the past and have symptoms of posttraumatic stress disorder (PTSD) currently. A person with PTSD may feel significant distress when reminded of a traumatic event or feel depressed, anxious or jumpy.

As a part of this study, participants will receive brain MRIs and office assessments before and after psychotherapy.  The investigators provide the gold-standard psychotherapy for PTSD, “Prolonged Exposure”, free of charge; additionally participants are compensated for their time during assessment procedures. This study is exploring the brain circuitry involved in improvement in response to psychotherapy.

Condition Intervention
Posttraumatic Stress Disorder (PTSD)                 Behavioral: Prolonged exposure                 Behavioral: Prolonged Exposure
Study Type:         Interventional
Study Design: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science
Official Title: The Neurobiology of Psychotherapy: Emotional Reactivity and Regulation in PTSD

Resource links provided by NLM:

MedlinePlus related topics:             Anxiety                 Post-Traumatic Stress Disorder

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:

  • Clinician Administered PTSD scale (CAPS) [ Time Frame: Before and after Prolonged Exposure Treatment, which is expected to take approximately six weeks. ] [ Designated as safety issue: No ]
    The CAPS is a 30-item structured interview that corresponds to the DSM-IV criteria for PTSD.  In addition to assessing the 17 PTSD symptoms, questions target the impact of symptoms on social and occupational functioning, improvement in symptoms since a previous CAPS administration, overall response validity, overall PTSD severity, and frequency and intensity of five associated symptoms (guilt over acts, survivor guilt, gaps in awareness, depersonalization, and derealization). For each item, standardized questions and probes are provided.

Secondary Outcome Measures:

  • Mood and Anxiety Symptom Questionnaire (MASQ) [ Time Frame: Before and after Prolonged Exposure Treatment, which is expected to take approximately six weeks. ] [ Designated as safety issue: No ]
    Treatment success based on Improvement on subscales of the MASQ, including decreased anxious arousal and decreased anhedonic depression, from pre- to post-treatment assessment
  • fMRI-assessed resting connectivity [ Time Frame: Before and after Prolonged Exposure Treatment, which is expected to take approximately six weeks. ] [ Designated as safety issue: No ]
    From pre- to post-treatment, improve will be based on enhanced functional connectivity
  • Implicit emotion regulation [ Time Frame: Assessed 4 times: Before beginning Prolonged Exposure, after the third week of therapy, after the last therapy session (on average 6 weeks after beginning therapy), and 1 month after the end of therapy. ] [ Designated as safety issue: No ]
    Implicit emotion regulation assessed through emotion conflict task performed during functional imaging. Performance based on reaction time and recruitment of emotion regulation regions during the task.
Estimated  Enrollment: 64
Study Start Date: September 2010
Estimated  Study Completion Date: September 2015
Estimated  Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)

             Arms                       Assigned Interventions          
          Experimental: Immediate Prolonged Exposure Treatment

Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. Participants in this arm will complete a concurrent TMS/fMRI scan before beginning Prolonged Exposure (PE). PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA.
                      Behavioral: Prolonged exposure

PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients’ day-to-day lives.
          No Intervention: Wait list, immediately followed by Prolonged Exposure

Intake procedures include clinician-administered diagnostic battery, cognitive testing, self-report measures of symptoms, and functional imaging scan. NOTE: Participants in this arm receive treatment following a waitlist period of 12 weeks.  After waitlist, will have a TMS/fMRI scan and then immediately begin Prolonged Exposure treatment. See above for description of Prolonged Exposure.
                      Behavioral: Prolonged Exposure

PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients’ day-to-day lives.

  Eligibility

Ages Eligible for Study: 18 Years to 60 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

  1. age between 18 and 60 years;
  2. fMRI scanning eligibility, including no evidence of any form of metal embedded in the body (e.g., metal wires, nuts, bolts, screws, plates, sutures), as these produce artifacts when brain imaging;
  3. not currently involved in an exposure-based psychotherapy, in order to be able to measure and interpret the effects of PE on PTSD;
  4. must comprehend English well and show non-impaired intellectual abilities to ensure adequate comprehension of the fMRI task instructions and PE treatment;
  5. no history of neurological or cardiovascular disorders, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, stroke, seizures or epilepsy, diabetes, hypo- or hyperthyroidism, head trauma with loss of consciousness greater than thirty minutes;
  6. no regular use of benzodiazepine, opiate, thyroid, anticonvulsant or antipsychotic medications. Patients on stable doses of antidepressant medications will be allowed. Patients for whom antidepressant dosing is being actively titrated will be required to be on a stable dose for 1 month prior to inclusion in the study.

Exclusion Criteria:

  • Any contraindication to being scanned in the 3T or 1.5T scanners at the Lucas Center or CNI such as having a pacemaker or implanted device that has not been cleared for scanning at the Lucas Center or CNI.
  • Participants will be excluded from the study if there is any lifetime evidence of psychosis, mania, hypomania, or bipolar disorders. Other axis I comorbidities will not be a cause for exclusion.

In addition, subjects will be excluded if they have a significant CNS neurological condition such as stroke, seizure, tumor, hemorrhage, multiple sclerosis, etc.

Patients who have current substance dependence will be excluded from the study. A recent diagnosis of substance abuse is allowable, however, as long as subjects have been abstinent for greater than three months.

  • Subjects will be excluded if they are currently in an exposure-based psychotherapy for PTSD.

  Contacts and Locations

    Please refer to this study by its ClinicalTrials.gov identifier: NCT01507948

Contacts
Contact: Kathy Peng, B.A. 650-725-9510 psychiatry@stanford.edu
Contact: Madeleine Goodkind, PhD 650-493-5000 ext 60168 mgoodkin@stanford.edu

  

Locations
United States, California
VA Palo Alto Healthcare System Recruiting
Palo Alto, California, United States, 94304
Contact: Kathy Peng, B.A.     650-725-9510     psychiatry@stanford.edu
Contact: Madeleine Goodkind, Ph.D.     650-493-5000 ext 60168     mgoodkin@stanford.edu
Principal Investigator: Amit Etkin, M.D., Ph.D.
Stanford University, Department of Psychiatry Recruiting
Stanford, California, United States, 94304
Contact: Kathy Peng, B.A.     650-725-9510     psychiatry@stanford.edu
Contact: Madeleine Goodkind, Ph.D.     650-725-9510     mgoodkin@stanford.edu
Principal Investigator: Amit Etkin, M.D., Ph.D.

Sponsors and Collaborators
Stanford University

Investigators
Principal Investigator: Amit Etkin, M.D., Ph.D. Stanford University
Study Director: Madeleine S Goodkind, Ph.D. Stanford University

  More Information

    Additional Information:

study webpage      This link exits the ClinicalTrials.gov site
study poster      This link exits the ClinicalTrials.gov site
study goals      This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT01507948             History of Changes
Other Study ID Numbers: SU-10252011-8566
Study First Received: December 14, 2011
Last Updated: January 13, 2012
Health Authority: United States: Institutional Review Board United States: Federal Government

       Keywords provided by Stanford University:

Posttraumatic Stress Disorder (PTSD)                     Psychotherapy                     non-medication treatment                     Prolonged Exposure Transcranial Magnetic Stimulation (TMS)                     Anxiety Disorders                     emotion                     emotion regulation                     functional MRI                     Affective Symptoms

       Additional relevant MeSH terms:

                    Stress Disorders, Post-Traumatic                     Stress Disorders, Traumatic                     Anxiety Disorders                     Mental Disorders

ClinicalTrials.gov processed this record on August 27, 2013

One Response to “Participants Needed for PTSD Clinical Trial At Stanford University / VA Medical Facility In Palo Alto, California”

  1. The following is in reference / per an on going thread located at post: “My Treatments For PTSD via TransCranial-Magnetic-Stimulation (TMS)”

    Hey Martin,…

    Congratulations on your acceptance into the trials for PTSD treatment.

    Can they(Stanford / VA) offer assistance of any kind to provide housing for you during the trial such as dormitory on campus, a room in someone’s house,…ect?
    Do you have any friends that may know someone that lives in that area (San-Fran Bay area / Peninsula that could provide short-term housing for you)?

    Howard Lovely, Jr.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: